Suloctidil
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.053.920 |
| Chemical and physical data | |
| Formula | C20H35NOS |
| Molar mass | 337.563 g·mol−1 |
| (verify) | |
Suloctidil was a sulfur-containing aminoalcohol that was brought to market in the early 1970s as a vasodilator by Continental Pharma, a Belgian company.[1]: 118–121 [2][3]
Continental was bought by Monsanto in 1984, primarily on the promise of sales of suloctidil, which was approved in Europe at the time, but not in the US.[4] However, in 1985 Monsanto halted development and withdrew the drug worldwide following reports of liver toxicity.[5]: 251
References
- ^ Hladovec J (1989). Antithrombotic Drugs in Thrombosis Models. CRC Press. ISBN 978-0-8493-5162-4.
- ^ Roncucci R, Roba J, Lambelin G, Ferenczi M, Blaton V, Vandamme D, Peeters H (March 1975). "Potential antilipolytic activity of suloctidil". Die Naturwissenschaften. 62 (3): 141–2. Bibcode:1975NW.....62..141R. doi:10.1007/bf00623284. PMID 1240601. S2CID 29484315.
- ^ BE granted 739678, Buu-Hoi NP, Lambelin G, Roba J, Jacques G, Gillet C, "1-Subst-phenyl-2-amino-ethanols useful as beta adrenergic agents peripheral vasodilators and hypotensive agents"
- ^ "Monsanto's $150 mil. Life Sciences Research Center". Pharma & Medteck Business Intelligence. 5 November 1984. Archived from the original on 2015-07-07.
- ^ "Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals" (PDF). Department of Economic and Social Affairs of the United Nations Secretariat. New York: United Nations. 2005.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |